Exicure (XCUR) Cash from Operations (2016 - 2026)
Exicure (XCUR) reported Cash from Operations of 1142000.0 for Q1 2026, up 28.54% on a YoY basis from 888469.33 in Q1 2025, and little changed quarter-over-quarter from 1147000.0 in Q4 2025.
Exicure (XCUR) Cash from Operations (2016 - 2026) Analysis & Trends
Exicure has reported Cash from Operations for 11 years, with the latest figure at 1142000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 28.54% year-over-year to 1142000.0; the trailing twelve-month figure through Mar 2026 stood at 8099000.0 (down 99.58% YoY), and the FY2025 full-year result was 8555000.0, down 193.99% from the prior year.
- Cash from Operations for Q1 2026 stood at 1142000.0, roughly flat from 1147000.0 in the prior quarter.
- The five-year high for Cash from Operations was 449000.0 in Q3 2024, with the low at 12756000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 3448352.94 across 5 years, with a median of 1598000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 88.79% — and 2025, when it plunged 685.75%.
- Exicure's Cash from Operations stood at 7276000.0 in 2022, then surged by 88.79% to 816000.0 in 2023, then dropped by 3.55% to 845000.0 in 2024, then slumped by 35.74% to 1147000.0 in 2025, then increased by 0.44% to 1142000.0 in 2026.
- The last three Cash from Operations figures came in at 1142000.0 (Q1 2026), 1147000.0 (Q4 2025), and 3528000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Exicure | 18.48 Mn | 15.88 Mn | - | -1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Dec 31, 2025 | -1.15 Mn |
| Sep 30, 2025 | -3.53 Mn |
| Sep 30, 2025 | -3.53 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -845,000.00 |
| Dec 31, 2024 | -845,000.00 |
| Sep 30, 2024 | -449,000.00 |
| Sep 30, 2024 | -449,000.00 |
| Jun 30, 2024 | -1.17 Mn |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -450,000.00 |
| Mar 31, 2024 | -450,000.00 |
| Dec 31, 2023 | -816,000.00 |
| Dec 31, 2023 | -816,000.00 |